2022 World Conference on Lung Cancer (ePosters)-EP08.01-041. Impact of Gender on Response to Immune Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer

EP08.01-041. Impact of Gender on Response to Immune Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer

Pdf Summary

This study aimed to evaluate the impact of gender on the response to immune checkpoint inhibitors in patients with non-small cell lung cancer (NSCLC) undergoing second- or later-line treatment. The study included 387 patients who received pembrolizumab, nivolumab, or atezolizumab as second- or later-line treatments. The researchers compared the progression-free survival (PFS) and overall survival (OS) scores based on gender and analyzed prognostic factors for immunotherapy response.<br /><br />The results showed that gender was not an independent prognostic factor for immunotherapy in real-world data. However, various factors such as wild type EGFR and high expression of PD-L1, which were more frequent in males, affected immunotherapy response. When considering treatment responses and selecting patients for immunotherapy, various factors that affect prognosis should be considered comprehensively.<br /><br />The study also found that male patients had higher smoking rates, PD-L1 expression, and expression of wild type EGFR, which are known as favorable prognostic factors. However, there was no difference in PFS and OS according to gender.<br /><br />Multivariate analysis revealed that ECOG performance status, high expression of PD-L1, and EGFR mutations were proposed as prognostic factors for PFS. ECOG performance status and squamous cell carcinoma were poor prognostic factors for OS. Gender was not found to be an independent prognostic factor for PFS and OS.<br /><br />The study concluded that gender does not have a significant impact on the response to immunotherapy in patients with NSCLC undergoing second- or later-line treatment. Other factors such as wild type EGFR and high expression of PD-L1 play a more crucial role in determining immunotherapy response. Therefore, when considering immunotherapy for NSCLC patients, these factors should be comprehensively evaluated.

Asset Subtitle

Jae Cheol Lee

Meta Tag

Speaker Jae Cheol Lee

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

gender

immune checkpoint inhibitors

NSCLC

second-line treatment

progression-free survival

overall survival

prognostic factors

immunotherapy response

wild type EGFR

PD-L1 expression